Clinical Efficacy of Lentinan on Neoplastic Diseases

  • Tetsuo Taguchi
  • Hisashi Furue
  • Tadashi Kimura
  • Tatsuhei Kondo
  • Takao Hattori
  • Nobuya Ogawa
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 166)

Abstract

Lentinan, a β-(1-3)-glucan with some β-(1-6)-gluco-pyranoside branchings, has been extracted and purified from Lentinus edodes a most popular edible mushroom in Japan. This substance has been shown to act as an immunostimulating agent through host defense mechanisms as reported by Chihara et al (1, 2). Lentinan exerts it’s antitumor activity on both syngeneic and spontaneous tumors. The cellular mechanisms of antitumor activity have been clarified by Hamuro et al (3), in that lentinan appears to stimulate host defense mechanisms to induce cytotoxic T cells, natural cytotoxicity and/or augmented macrophages against tumor cells. This suggests that lentinan may be effective for patients with malignant diseases. Based on the results of Phase I and II clinical trials conducted by Taguchi et al (4), the administration conditions for lentinan have been determined to be intravenous administration at doses of 0.5 to 1.0 mg/person/day once or twice a week in combination with chemotherapeutic agents for patients with advanced or recurrent cancer. In order to clarify the clinical efficacy of lentinan administration a Phase III randomized control trial has been conducted on patients with advanced or recurrent gastric or colorectal cancer.

Keywords

Gastric Cancer Combine Treatment Group Recurrent Gastric Cancer Natural Cytotoxicity Recurrent Colorectal Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chihara, G., Y. Y. Maeda, J. Hamuro, T. Sasaki, and F. Fukuoka. 1969. Inhibition of mouse sarcoma 180 by the polysaccharides from Lentinus edodes (Berk). Sing. Nature 222: 687–688.CrossRefGoogle Scholar
  2. 2.
    Maeda, Y. Y., J. Hamuro, Y. Yamada, K. Ishimura and G. Chihara. The nature of immunopotentiation by the antitumor polysaccharide Lentinan and the significance of biogenic amines in its action, p. 259. In G. E. W. Solstenholme and J. Knight (eds.), Immunopotentiation. Chiba Foundation Symposium, 18, Excerpta Medica, Amsterdam.Google Scholar
  3. 3.
    Hamuro, J., and G. Chihara. 1982. Chapter 29. In A. Szentivanyi and J. R. Battisto (eds.), A comprehensive treatise. Plenum Press, New York.Google Scholar
  4. 4.
    Taguchi, T., T. Aoki, H. Furue, and H. Mazima. Phase I and Phase II studies of lentinan. In T. Aoki, I. Urushizaki and E. Tsubura (eds.), Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam.Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • Tetsuo Taguchi
    • 1
  • Hisashi Furue
    • 2
  • Tadashi Kimura
    • 3
  • Tatsuhei Kondo
    • 4
  • Takao Hattori
    • 5
  • Nobuya Ogawa
    • 6
  1. 1.Research Institute for Microbial DiseasesOsaka UniversityOsakaJapan
  2. 2.Department of Internal MedicineTeikyo UniversityTokyoJapan
  3. 3.Department of SurgeryNational Medical Center Tokyo HospitalTokyoJapan
  4. 4.IInd Deparment of SurgeryNagoya UniversityNagoyaJapan
  5. 5.Department of Surgery, Research Institute for Nuclear Medicine and BiologyHiroshima UniversityHiroshimasJapan
  6. 6.Department of PharmacologyEhime UniversityMatsuyamaJapan

Personalised recommendations